OCS OCS
Company Profile ↓Company Overview
OCS (OCS) is a publicly traded company listed on with a market capitalization of $708.37M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -32.72% |
| 6 Months: | -57.12% |
| 3 Months: | -56.50% |
| 1 Month: | -10.99% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 19.97M | 20.77M | 20.30M | 20.63M | 21.73M |
| Operating Income | - | -19.97M | -20.77M | -20.30M | -20.63M | -21.73M |
| EBITDA | - | -32.84M | -25.10M | -16.53M | -23.30M | -28.62M |
| Interest Expense | - | 247.00K | 183.00K | 162.00K | 241.00K | 173.00K |
| Pretax Income | - | -33.21M | -25.40M | -16.84M | -23.70M | -28.95M |
| Tax Provision | - | 7.00K | -24.00K | 13.00K | -182.00K | -98.00K |
| Net Income | - | -33.21M | -25.38M | -16.86M | -23.51M | -28.85M |
| Diluted EPS | - | -0.69 | -0.49 | -0.32 | -0.42 | -0.49 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 32.38M | 45.85M | 73.20M | 81.67M |
| Operating Income | -32.38M | -45.85M | -73.20M | -81.67M |
| EBITDA | -31.90M | -87.09M | -84.89M | -97.76M |
| Interest Expense | 6.44M | 1.31M | 639.00K | 833.00K |
| Pretax Income | -38.64M | -88.69M | -85.94M | -99.14M |
| Tax Provision | 55.00K | 107.00K | -160.00K | -186.00K |
| Net Income | -38.70M | -88.80M | -85.78M | -98.96M |
| Diluted EPS | -11.32 | -2.97 | -2.12 | -1.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 37.06M | 114.35M | 120.35M | 235.96M |
| Current Assets | - | 23.66M | 101.02M | 104.90M | 218.89M |
| Cash & Equivalents | - | 19.79M | 38.33M | 27.71M | 81.33M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.08M | 1.20M | 1.51M | 1.79M |
| Total Liabilities | - | 135.05M | 20.62M | 46.97M | 39.89M |
| Current Liabilities | - | 12.02M | 19.09M | 44.23M | 36.75M |
| Long Term Debt | 113.50M | 122.45M | - | - | - |
| Total Debt | - | 633.00K | 605.00K | 1.18M | 2.31M |
| Total Equity | - | -97.99M | 93.73M | 73.38M | 196.07M |
| Shares Outstanding | - | 32.73M | 36.65M | 44.66M | 58.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.07M | -55.04M | -48.92M | -66.30M |
| Investing Cash Flow | - | -3.55M | -52.97M | -16.08M | -60.93M |
| Financing Cash Flow | - | 1.71M | 129.63M | 53.98M | 186.92M |
| Capital Expenditure | - | -3.55M | -48.00K | -230.00K | -1.39M |
| Free Cash Flow | - | -28.62M | -55.09M | -49.15M | -67.69M |
| Net Change in Cash | - | -26.91M | 21.62M | -11.03M | 59.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 39.5% | -94.7% | -116.9% | -50.5% |
| ROCE % | -129.3% | -48.1% | -96.2% | -41.0% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OCS
FDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPUTBYbEU4V2hZYmM3RjNWNjhhd3BiM1VSTl9nb01GMFdtYjd0U2ttQnVlSnk3cGZIV2R1ZWwwN2h0aDF4YVNZLU85WkZ0NF9uRFcwNUl1aGRtN2JWcEdYNnhpSWFKVWRzcUJPT1pxdFA4ZDhjcEpfRkpYREloTkc4c3U3N0R1QnNReDZWZD…
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOSWkyb2w3bEFVRVdjYkdLQ2J6N3hGbTRxTVB6RmN6VXhXRXhvNFhRSVlxQXBhRzEyZm9ENjJNUnBBekV0MmhvRVlVUVBhUzltcDdRVkZjOEZ2ME9xekN0d2JJYmM2ZGk1SmxFaUVvWGtMYzJtbFhmWEhINk54WjVFUlpUWWRXTndoVGhVUT…
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPQVduM2JHOEpzQm00WFg5dXNEeXJOOHkxNnpIME5sc01scExiUTFXZmhKT0hUMlVKRE1EaGJDVHJoMEhFbi1SRzduZHptSkxxTHVENk1JVkQwYzc4aTNjT19KZ095VEx0VHZzWURwcDlsZDdOTENWVkFBY01GYTN3SVJkUllYWHhhOFEzU1…
OCS Stock Price and Chart — NASDAQ:OCS - TradingView
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5EZ1h6UmxTWEhMX19IMXlHcE1fN1BFSm81cncwR25HMnVodExBenhHbjNObkR0bHROQlRyZDNJalNLeDVLZWE3N1dJOGFaeEFrbjZWVlduXzFkNzQ?oc=5" target="_blank">OCS Stock Price and Chart — NASDAQ:OCS</a>&n…
UK contractor Mitie agrees to $4.2 billion takeover by PE-backed rival, shares jump - Reuters
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPdXJocEtOczBRZ2pOWHdMNW40TmpwU3dYWE5FbXV5M1lpT08waHY0RjJuZ3JKaktfZDRYVUJaa2ozLW50RGozSlQtRmI3WkJ1MVY0U2JaNlhhM2o4eWZDUHFnT3dnT3Q3U0lhRUNlX2M4UEx4RUlzcFA3MmZGMnlwMXQyQzVyVHRqc3RtOX…
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxQYURKUUR4X3B2bDdMeGdUM2RHRXk2YjVHTmcxTDBXT1A0TGlUUGFLckNhR29XbUVlajFjN3oyMThiZzBBcWlZMmJuZllCeXlSNWp5WlotV1FpYlg1ZDJyclBIZXJDU0NXVVZZMEtzMmZNTUtNbGhsUm93SUl6NXkwWjFpcjVRMHhsV3N5cz…
OCS — Frequently Asked Questions
What is the current share price of OCS?
As of 2026-08-05 17:25 PDT, OCS trades at $12.07 on NASDAQ/NYSE. Its 52-week range is $10.71 to $32.65.
What is the market capitalisation of OCS?
OCS has a market capitalisation of $708.37M on NASDAQ/NYSE.
What is the P/E ratio of OCS?
OCS trades at a trailing price-to-earnings (P/E) ratio of -6.39. Its price-to-book (P/B) ratio is 3.61.
What is the return on equity (ROE) of OCS?
OCS has a return on equity (ROE) of -50.47%. Its return on capital employed (ROCE) is -41.00%.
Is OCS a good stock to buy?
This page provides a data-driven analysis of OCS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.